Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$13.04 -1.3%	$13.88	$10.57 ▼ $33.33	$1.89B	1.49	1.10 million shs	1.21 million shs
IMVT Immunovant	$14.10 -1.3%	$15.15	$12.72 ▼ $34.47	$2.40B	0.75	1.23 million shs	1.43 million shs
KRYS Krystal Biotech	$123.36 -2.4%	$157.54	$122.80 ▼ $219.34	$3.56B	0.79	308,404 shs	268,449 shs
RVMD Revolution Medicines	$37.73 +2.1%	$37.53	$29.17 ▼ $62.40	$7.03B	1.11	1.51 million shs	2.27 million shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	-1.29%	-4.75%	-19.75%	-29.89%	-31.01%
IMVT Immunovant	-1.33%	-2.15%	-8.56%	-30.37%	-50.39%
KRYS Krystal Biotech	-2.44%	-2.62%	-27.32%	-28.84%	-22.42%
RVMD Revolution Medicines	+2.06%	-2.61%	-9.02%	-3.45%	-0.45%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.5179 of 5 stars	4.5	1.0	4.7	4.3	2.5	0.0
IMVT Immunovant	2.2401 of 5 stars	4.5	0.0	0.0	2.9	1.7	0.0
KRYS Krystal Biotech	4.8846 of 5 stars	4.5	1.0	4.7	4.1	3.3	1.9
RVMD Revolution Medicines	4.2677 of 5 stars	4.5	0.0	4.7	3.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	158.55% Upside
IMVT Immunovant	2.90	Moderate Buy	$38.33	171.87% Upside
KRYS Krystal Biotech	3.00	Buy	$211.13	71.15% Upside
RVMD Revolution Medicines	3.00	Buy	$67.08	77.80% Upside

Current Analyst Ratings Breakdown

Latest KRYS, DNLI, RVMD, and IMVT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/16/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$215.00 ➝ $155.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00
5/8/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00 ➝ $57.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/7/2025	KRYS Krystal Biotech	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$195.00 ➝ $189.00

(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	5.73	N/A	N/A	$7.42 per share	1.76
IMVT Immunovant	N/A	N/A	N/A	N/A	$2.08 per share	N/A
KRYS Krystal Biotech	$333.45M	10.69	$3.13 per share	39.38	$32.85 per share	3.76
RVMD Revolution Medicines	$742K	9,471.55	N/A	N/A	$11.09 per share	3.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	8/7/2025 (Estimated)
IMVT Immunovant	-$259.34M	-$2.62	N/A	N/A	N/A	N/A	-77.94%	-69.82%	6/4/2025 (Estimated)
KRYS Krystal Biotech	$10.93M	$4.16	41.26	12.24	N/A	30.69%	11.41%	10.40%	8/4/2025 (Estimated)
RVMD Revolution Medicines	-$436.37M	-$4.00	N/A	N/A	N/A	N/A	-33.67%	-30.08%	8/6/2025 (Estimated)

Latest KRYS, DNLI, RVMD, and IMVT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/4/2025	Q4 2025	IMVT Immunovant	-$0.72	N/A	N/A	N/A	N/A	N/A
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	KRYS Krystal Biotech	$1.38	$1.20	-$0.18	$1.20	$98.66 million	$88.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
IMVT Immunovant	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.98	9.98
IMVT Immunovant	N/A	6.04	6.04
KRYS Krystal Biotech	N/A	7.28	7.76
RVMD Revolution Medicines	N/A	14.24	14.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
IMVT Immunovant	47.08%
KRYS Krystal Biotech	86.29%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
IMVT Immunovant	5.90%
KRYS Krystal Biotech	13.70%
RVMD Revolution Medicines	8.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
IMVT Immunovant	120	169.86 million	159.84 million	Optionable
KRYS Krystal Biotech	210	28.90 million	24.71 million	Optionable
RVMD Revolution Medicines	250	186.27 million	154.76 million	Optionable

KRYS, DNLI, RVMD, and IMVT Headlines

Recent News About These Companies

Revolution Medicines (NASDAQ:RVMD) Trading Down 4% - Here's Why

May 28 at 1:06 PM | marketbeat.com

Polar Asset Management Partners Inc. Boosts Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 28 at 5:36 AM | marketbeat.com

Revolution Medicines’ SWOT analysis: stock shows promise amid clinical progress

May 27 at 8:58 PM | investing.com

Nuveen Asset Management LLC Raises Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 26 at 3:51 AM | marketbeat.com

D. E. Shaw & Co. Inc. Decreases Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 26 at 3:34 AM | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by ProShare Advisors LLC

May 23, 2025 | marketbeat.com

Bank of America Corp DE Has $17.54 Million Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 23, 2025 | marketbeat.com

Woodline Partners LP Has $169.96 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 22, 2025 | marketbeat.com

Soleus Capital Management L.P. Sells 503,500 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 21, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

May 21, 2025 | marketbeat.com

Revolution Medicines Inc.

May 20, 2025 | wsj.com

Tang Capital Management LLC Invests $4.37 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

Tema Etfs LLC Invests $1.99 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

Man Group plc Buys 65,567 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

Deutsche Bank AG Has $7.76 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 20, 2025 | marketbeat.com

Polar Asset Management Partners Inc. Buys 10,900 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 19, 2025 | marketbeat.com

Polar Capital Holdings Plc Invests $32.83 Million in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 18, 2025 | marketbeat.com

Jefferies Financial Group Inc. Buys New Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 18, 2025 | marketbeat.com

MPM Bioimpact LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD)

May 16, 2025 | marketbeat.com

Revolution Medicines, Inc. (NASDAQ:RVMD) is Paradigm Biocapital Advisors LP's 4th Largest Position

May 16, 2025 | marketbeat.com

Nextech Invest Ltd. Buys 1,304,347 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

May 16, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
By Thomas Hughes | May 27, 2025
View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings
Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
By Leo Miller | May 27, 2025
View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook
Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
By Sam Quirke | May 14, 2025
View Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore

KRYS, DNLI, RVMD, and IMVT Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$13.04 -0.17 (-1.29%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$13.03 -0.01 (-0.08%)

As of 05/28/2025 06:59 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Immunovant NASDAQ:IMVT

$14.10 -0.19 (-1.33%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$14.41 +0.31 (+2.20%)

As of 05/28/2025 07:55 PM Eastern

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

Krystal Biotech NASDAQ:KRYS

$123.36 -3.09 (-2.44%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$123.41 +0.05 (+0.04%)

As of 05/28/2025 04:23 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Revolution Medicines NASDAQ:RVMD

$37.73 +0.76 (+2.06%)

Closing price 05/28/2025 04:00 PM Eastern

Extended Trading

$37.40 -0.33 (-0.89%)

As of 05/28/2025 07:09 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time